Trials / Completed
CompletedNCT01579994
Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
About 18 patients will take part in the phase 1 portion of the trial. In the beginning of the study, 3 patients will be treated with a low dose of ganetespib (STA-9090) and the standard dose of crizotinib. If this dose does not cause significant side effects, it will be increased as new patients take part in the study. The study will only be open at Memorial Sloan Kettering Cancer Center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganetespib (STA-9090) and crizotinib | Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion. |
Timeline
- Start date
- 2012-04-16
- Primary completion
- 2020-12-28
- Completion
- 2020-12-28
- First posted
- 2012-04-18
- Last updated
- 2020-12-30
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01579994. Inclusion in this directory is not an endorsement.